Pharmacology  ·  Antiparkinson Drugs

Levodopa and Carbidopa

Mechanism, benefits of combination, and clinical profile

• Dopamine itself cannot enter the brain — it is charged and water-soluble, blocked by blood-brain barrier tight junctions; levodopa bypasses this by traveling as a neutral amino acid via the large neutral amino acid transporter.
• Once inside the brain, aromatic amino acid decarboxylase (AAAD) converts levodopa to dopamine, replenishing striatal dopamine at the site of greatest need.
• Carbidopa is a peripheral AAAD inhibitor that cannot cross the blood-brain barrier — it blocks levodopa-to-dopamine conversion in the gut, liver, and bloodstream, delivering roughly 75% more levodopa to the brain per dose.
• The carbidopa combination reduces the required levodopa dose by ~75%, substantially decreases peripheral dopamine-driven nausea and orthostatic hypotension, and minimizes cardiovascular side effects.
• The most important long-term complications are motor fluctuations (wearing-off, on-off) and dyskinesias — covered in Module 3 — and neuropsychiatric effects (hallucinations, psychosis) from mesolimbic dopamine excess, which is more common in older patients.